Names |
- Cutaneous Leukocytoclastic vasculitis
- Hypersensitivity angiitis (subtype)
- Hypersensitivity Vasculitis
- Leucocytoclastic vasculitis
- Microscopic polyarteritis
Abbreviations: MPA, LCV Category: Vascular system |
Prevalence |
No data on US prevalence. Female/Male ratio: 3.0x. |
Age of Onset |
No data. |
Description |
Microscopic polyangiitis (MPA) is a disorder that causes inflammation in the blood vessels. The inflammation can affect many of the body's organ systems including the kidneys, nervous system, skin, lungs, etc. Microscopic polyangiitis is believed to be autoimmune because the development of the disease is thought to come from an overreaction in the immune system that causes inflammation in the body's tissues and blood vessels. The disease can be confused with others such as polyarteritis nodosa (PAN), granulomatosis with polyangiitis (GPA), and cutaneous leukocytoclastic angiitis (CLA). However, in 1994, The Chapel Hill Consensus Conference defined MPA as a separate disorder.
Evidence of autoimmunity: Antibody
|
Patient Groups |
|
Bloggers |
|
Symptoms |
|
Resources |
Link to Clinical Trials Link to PubMed |
References |
Link to Cleveland Clinic
Link to Healthline
|
|
Profile by: Lauren DunnProfile updated September 2024Charts generated Nov 16, 2024 at 09:55 AM ET |
|
Microscopic polyangiitis sex breakdown
Please wait while the Microscopic polyangiitis sex breakdown results are loaded
Microscopic polyangiitis age breakdown
Please wait while the Microscopic polyangiitis age breakdown results are loaded
|
Data Source: Graphs on this page represent data in electronic health records and self-reported survey results from the All of Us research database. As of July 2024, there are 451,000 sets of electronic health records and over 560,000 participants who have completed initial survey questions. This dataset, however, may not be representative of the US population. A snapshot of the data can be found
here. To protect participant anonymity, results derived from fewer than 20 participants are not graphed.
The All of Us Research Program is supported by the National Institutes of Health, Office of the Director: Regional Medical Centers: 1 OT2 OD026549; 1 OT2 OD026554; 1 OT2 OD026557; 1 OT2 OD026556; 1 OT2 OD026550; 1 OT2 OD 026552; 1 OT2 OD026553; 1 OT2 OD026548; 1 OT2 OD026551; 1 OT2 OD026555; IAA #: AOD 16037; Federally Qualified Health Centers: HHSN 263201600085U; Data and Research Center: 5 U2C OD023196; Biobank: 1 U24 OD023121; The Participant Center: U24 OD023176; Participant Technology Systems Center: 1 U24 OD023163; Communications and Engagement: 3 OT2 OD023205; 3 OT2 OD023206; and Community Partners: 1 OT2 OD025277; 3 OT2 OD025315; 1 OT2 OD025337; 1 OT2 OD025276. In addition, the All of Us Research Program would not be possible without the partnership of its participants.
Microscopic polyangiitis top comorbidities/symptoms
Please wait while the Microscopic polyangiitis top comorbidities/symptoms results are loaded
Microscopic polyangiitis top autoimmune comorbidities
Please wait while the Microscopic polyangiitis top autoimmune comorbidities results are loaded
* Disease is suspected as autoimmune, but unconfirmed. Data Source: Graphs on this page represent data in electronic health records from the All of Us research database. As of July 2024, there are 451,000 sets of electronic health records collected from participants. In the United States, because electronic health records use billing codes for diagnoses, some conditions may not be perfectly captured by these data, especially if the condition is rare. A snapshot of the data can be found
here. To protect participant anonymity, results derived from fewer than 20 participants are not graphed.
The All of Us Research Program is supported by the National Institutes of Health, Office of the Director: Regional Medical Centers: 1 OT2 OD026549; 1 OT2 OD026554; 1 OT2 OD026557; 1 OT2 OD026556; 1 OT2 OD026550; 1 OT2 OD 026552; 1 OT2 OD026553; 1 OT2 OD026548; 1 OT2 OD026551; 1 OT2 OD026555; IAA #: AOD 16037; Federally Qualified Health Centers: HHSN 263201600085U; Data and Research Center: 5 U2C OD023196; Biobank: 1 U24 OD023121; The Participant Center: U24 OD023176; Participant Technology Systems Center: 1 U24 OD023163; Communications and Engagement: 3 OT2 OD023205; 3 OT2 OD023206; and Community Partners: 1 OT2 OD025277; 3 OT2 OD025315; 1 OT2 OD025337; 1 OT2 OD025276. In addition, the All of Us Research Program would not be possible without the partnership of its participants.
* Biologic medications. Data Source: Graphs on this page represent data in electronic health records from the All of Us research database. As of July 2024, there are 451,000 sets of electronic health records collected from participants. A snapshot of the data can be found
here. To protect participant anonymity, results derived from fewer than 20 participants are not graphed.
The All of Us Research Program is supported by the National Institutes of Health, Office of the Director: Regional Medical Centers: 1 OT2 OD026549; 1 OT2 OD026554; 1 OT2 OD026557; 1 OT2 OD026556; 1 OT2 OD026550; 1 OT2 OD 026552; 1 OT2 OD026553; 1 OT2 OD026548; 1 OT2 OD026551; 1 OT2 OD026555; IAA #: AOD 16037; Federally Qualified Health Centers: HHSN 263201600085U; Data and Research Center: 5 U2C OD023196; Biobank: 1 U24 OD023121; The Participant Center: U24 OD023176; Participant Technology Systems Center: 1 U24 OD023163; Communications and Engagement: 3 OT2 OD023205; 3 OT2 OD023206; and Community Partners: 1 OT2 OD025277; 3 OT2 OD025315; 1 OT2 OD025337; 1 OT2 OD025276. In addition, the All of Us Research Program would not be possible without the partnership of its participants.